Belite Bio, Inc
BLTE
Rank in Stocks
#3149
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Share Price
$143.80
Last synced: 2026-10-16
Market Cap
$5.74B
Change (1 day)
-5.78%
Change (1 year)
63.95%
Country
US
Trade Belite Bio, Inc (BLTE)
Category
Healthcare
EPS for Belite Bio, Inc (BLTE)
EPS as of June 2026 TTM: $-2.76
According to Belite Bio, Inc latest financial reports and stock price the company's current EPS (TTM) is $-2.76. At the end of 2023 the company had a EPS of $-1.19 an increase over its 2022 EPS that were of $-0.63.
EPS history for Belite Bio, Inc from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.76 | 133.90% |
| 2024 | $-1.18 | -0.84% |
| 2023 | $-1.19 | 88.89% |
| 2022 | $-0.63 | 57.50% |
| 2021 | $-0.40 | -35.48% |
| 2020 | $-0.62 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -727.54% |
US
|
|
| $-7.98 | 189.13% |
US
|
|
| $-5.29 | 91.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,105.07% |
NL
|
